Introduction
The potential of enlisting the immune system as an endogenous tumouricidal therapy has been realised in recent clinical trials of inhibitors of immune checkpoint proteins such as cytotoxic Tlymphocyte associated protein 4 (CTLA4) [1] , programmed cell death 1 (PD-1) [2] and programmed death ligand 1 (PD-L1) [3, 4] . PD-L1 binds PD-1 [5, 6] and CD80 [7] to reduce the cellular immune response by inducing T-cell tolerance which, amongst other roles, helps prevent autoimmunity in certain organs and is thought to act as a mechanism of immune evasion by tumours [8] . Therefore inhibition of PD-L1 will, in a sense, 'release the brakes' on the immune response enabling an unfettered T-cell mediated attack. In solid tumours PD-L1 has been found to be expressed by both tumour cells and infiltrating immune cells [4, 9] and its inhibition has been found to result in an enduring clinical response in a variety of solid tumours including melanoma [1] , renal cell carcinoma [3] , lung carcinoma [3] and, most recently, bladder carcinoma [4] . Breast cancer has not generally been thought of as an immunogenic malignancy and, unlike bladder cancer, no therapy designed to enhance the anti-tumour immune response is currently used. However, breast cancer is an exceptionally heterogeneous disease and it has become apparent that a subset of tumours is subject to an effective immune response. In a large scale analysis of four studies we found that the presence of infiltrating cytotoxic T-cells was associated with improved outcome but that this effect was limited to ER-negative and HER2-positive disease [10] .
Since clinical trials have found that expression of PD-L1 on both tumour and immune cells predicts whether a patient is likely to respond to its inhibition [9] , we used large clinical studies to investigate the prevalence of PD-L1 expression in breast cancer in order to estimate the proportion of the population that may benefit from these therapies.
Methods

Patient population
Primary tumour samples from three clinical studies were used for this analysis: the SEARCH observational study [11] , the NEAT randomised controlled trial [12] and the METABRIC genomic study [13, 14] . Patient characteristics are summarised in Supplementary Table 1 . Details of clinical studies are provided in Supplementary Methods.
Molecular subtyping
Tumour molecular subtype was assigned using both combined copy-number and expression profiling for tumours from the METABRIC study [13, 15] and a surrogate immunohistochemical classifier for the SEARCH and NEAT studies [16] which is summarised in Supplementary Table 2 . Genomic instability and TP53 status were determined as previously described [13, 17, 18] . Further details are provided in the Supplementary Methods.
PD-L1 assay validation and scoring
A rabbit monoclonal antibody raised against residues near the carboxy terminus of PD-L1 (Cell Signalling Technology, catalogue #13684) was investigated for use in immunohistochemistry (IHC).
Two breast cancer cell lines (MDA-MB-231 and MCF7) were used to assess the specificity of the antibody by western blot analysis. To modulate PD-L1 expression, cell lines were treated with interferon gamma and knockdown experiments were conducted using siRNA directed against human CD274 (PD-L1). Specificity of the immunohistochemical assay was tested using formalin fixed paraffin embedded pellets of the cell lines with concurrent quantitative western blot analysis of fresh cell lysates for comparison. Detailed experimental procedures are described in Supplementary Methods. Tumour samples were represented by a single 0.6 mm core in tissue microarrays. Stained slides were scanned using an Aperio Scanscope AT2 digital slide scanner. PD-L1 was scored as reported in recent trials [9] was used where tumour and immune cells were attributed separate scores on a four- 
Statistical analyses
Correlations between continuous and ordinal variables were assessed using Spearman's rank correlation coefficient. Associations between categorical variables were assessed using Pearson's chisquared test. The Kruskal-Wallis rank test was used to investigate the relationship between CD274 (PD-L1) copy number status and gene expression. The relationship between expression of PD-L1 and 
Results
PD-L1 assay validation
Western blot analysis using a rabbit monoclonal antibody detected a protein of 50 kDa, approximately the size of glycosylated PD-L1 [19] , Figure 2E ) consistent with previous observations [19] .
Collectively these analyses confirmed the specificity of the immunohistochemical assay for PD-L1.
CD274 (PD-L1) amplification occurs in a subset of almost exclusively basal-like tumours
We used the METABRIC dataset comprising 1,980 tumours to investigate the relationship between CD274 (PD-L1) copy-number status, gene and protein expression and molecular subtype ( Figure 1 ). 
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PD-L1 protein is rarely expressed in breast cancer
Data on expression of PD-L1 was successfully generated in 3916 tumours from the SEARCH (N=2453) and NEAT (N=1463) studies (Supplementary Figure 6) ; data was not generated on the 
Association with disease specific survival
Expression of PD-L1, by either tumour cells or immune cells, was not significantly associated with outcome in either ER-positive or ER-negative breast cancer (Supplementary Tables 3 and 4) irrespective of whether the variable was modelled as categorical, continuous or dichotomous.
However, in ER-negative disease, a subgroup in which immune infiltration has previously been found to be associated with outcome [10] , PD-L1 expression in >10% of immune cells was associated with reduced disease specific mortality although this was nominally statistically significant (HR 0.53, 95%
CI 0.26-1.07; P=0.08). There was no significant interaction between the prognostic effect of cytotoxic or regulatory T-cells and PD-L1 expression nor was any significant interaction between randomisation arm in the NEAT trial and PD-L1 (data not shown). Supplementary Table 5 details estimates of absolute survival at five and ten years for patient subgroups defined by PD-L1 expression, the presence of intra-tumoural CD8 + (iT-CD8) lymphocytes and ER-status. These estimates require cautious interpretation owing to the rarity of PD-L1 expression.
Discussion
We This study is the first large scale analysis of PD-L1 protein expression in breast cancer. Previous studies have included many fewer patients [20] and their analytic validity has been questioned [21, 22] .
We used a validated assay and two large clinical studies including a population-based cohort in order to derive reliable estimates of the probable prevalence of PD-L1 expression in the breast cancer population. We report lower frequencies of PD-L1 expression than previous studies. Two prior studies evaluated PD-L1 at the level of gene expression using RNA fluorescence in situ (FISH) in one [23] , and pooled microarray data in the other [24] . Based on RNA FISH, Schalper et al. report that up to 60% of breast tumours show CD274 (PD-L1) expression [23] whereas Sabatier et al. report that CD274 (PD-L1) is upregulated in 20% of tumours based on microarray data [24] . These estimates themselves differ enormously and both are far greater than the frequencies observed here. This disparity may be due to the poor correlation between PD-L1 protein and RNA, as well as differences between study populations.
Although we find that PD-L1 expression is rare overall and though expressed in around one-fifth of basal-like tumours, clinical benefit from inhibition of PD-L1 may extend beyond this population.
Recent studies have shown, based both in mouse models [25] and human tumour samples [26, 27] , that mutational patterns can influence the efficacy of immune checkpoint inhibitors. Most notable amongst these characteristics are mutations which result in genetic alterations predicted to be immunogenic to the individual's immune system by encoding neo-antigens. Identifying the best predictor of immune checkpoint inhibition whether it's genomic, tissue based or a combination, will necessitate a head-to-head comparison in representative clinical cohorts of sufficient size.
We did not find a convincing association between PD-L1 expression by immune cells and clinical outcome. There was, however, a nominally significant association between high levels (>10%) of immune cell PD-L1 expression and improved survival (P=0.08). Given that both Schalper et al. and
Sabatier et al. report a significant association between high CD274 (PD-L1) gene expression and improved survival [23, 24] , it is plausible that we did not robustly detect this effect owing, for example, to a different threshold for 'high' PD-L1 expression or due to insufficient power. This difference may be addressed by pooling data from additional studies and using a quantitative system for scoring PD-L1 expression. However, our findings are supportive of the association between improved survival and PD-L1 expression previously reported.
The main limitation of this study was the use of TMAs for representation of tumours. In some tumours immune infiltration may be heterogeneous and this heterogeneity will not be captured by
TMAs. However, the reduced power associated with this sampling error was here attenuated by a large sample size. Indeed, TMAs enable the conduct of large scale pathology studies and in this way ultimately lead to more reliable conclusions. A second limitation is that we have not assessed PD-L1
protein expression in the metastatic setting in which trials of PD-L1 inhibitors have so far been conducted.
We find that PD-L1 protein expression is rare in primary breast cancer overall but that around one with tumours that express PD-L1, most of which will prove to be basal-like. Previous observations, both in cell-lines and in tumour samples are concordant with this conclusion [30] .
Conclusions
To our knowledge we have conducted the first large scale analysis of PD-L1 protein expression in breast cancer. We find that PD-L1 expression, both by immune and tumour cells is rare, associated with infiltrating lymphocytes and significantly enriched in basal-like tumours. Our findings together with those previously published [23, 24] suggest that high PD-L1 expression is associated with improved survival. These findings imply that clinical trials of PD-L1 inhibitors in breast cancer ought to be enriched for patients with basal-like breast cancer and, given the rarity of expression, may need to recruit across a large number of centres. 
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